N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=62 Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Overactive Bladder
Primary: Mean Change of the Total Frequency Per 3 Days — -4.64; -0.19 Frequency per 3 days
Phase 3 N=189 A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment (EoT) in Mean Volume Voided (MVV) Per Micturition — 13.4; 25.5; 6.9; 2.3 mL — p=0.046
Phase 3 N=248 Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
Urinary Bladder, Overactive
Primary: Treatment Phase 1 (Treatment Cycle 1): Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 12 After the First Treatment — -1.25…
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Phase 4 N=132 Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence
Urinary Bladder, Overactive
Primary: Change in OAB Symptoms Post Pubovaginal Sling Operation — 63; 21; 4 participants — p=0.001
N/A N=18 Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
Overactive Bladder
Primary: Number of Subjects With Evidence of Bacteria in Urine Sample by Microbiologic Evaluation — 8; 1 participants
Phase 4 N=249 A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
Urge Incontinence · Overactive Bladder (OAB)
Primary: Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group — -3.76 micturitions per 24 hours…
Phase 2 N=1,395 A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
Urinary Bladder, Overactive
Primary: Base Study/Part 1: Change From Baseline in Average Daily Micturitions at Week 8 — -1.16; -1.62; -1.61; -1.80 Micturitions — p=0.056
Phase 2 N=134 Bacterial Genomic Sequencing in Overactive Bladder
Overactive Bladder
Primary: Bacterial Genomic Sequencing — 25; 11; 3; 6 participants
Phase 4 N=70 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)
Overactive Bladder
Primary: Change in Mean Number of Micturition Episodes Per 24 Hours — -1.9; -2.2 episodes
Phase 3 N=90 Clinical Trial Comparing Two Bladder Instillations for IC/BPS
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire — -6.7; -5.8 scores on a scale
Early Phase 1 N=4 High Frequency SARS for Neurogenic Bladder and Bowel Emptying
Spinal Cord Injury
Primary: Urethral Sphincter Pressure — 50 cmH2O
N/A N=65 Study of Weekly Radiotherapy for Bladder Cancer
Bladder Cancer
Primary: Proportion of Patients Experiencing Severe Acute Non-genitourinary Side Effects Following Radiotherapy. — 4; 2 Participants
Phase 4 N=20 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants